Pazopanib in the treatment of advanced solitary fibrous tumour - Authors' reply

Lancet Oncol. 2019 Mar;20(3):e128. doi: 10.1016/S1470-2045(19)30080-4.

Authors

Javier Martin-Broto¹, David S Moura², Nadia Hindi³

Affiliations

¹ Instituto de Biomedicina de Sevilla (IBIS), Sevilla 41013, Spain; Department of Medical Oncology, University Hospital Virgen del Rocío, Sevilla, Spain. Electronic address: jmartin@mustbesevilla.org.
² Instituto de Biomedicina de Sevilla (IBIS), Sevilla 41013, Spain.
³ Instituto de Biomedicina de Sevilla (IBIS), Sevilla 41013, Spain; Department of Medical Oncology, University Hospital Virgen del Rocío, Sevilla, Spain.

PMID: 30842052
DOI: 10.1016/S1470-2045(19)30080-4

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Indazoles
Pyrimidines*
Solitary Fibrous Tumors*
Sulfonamides

Substances

Indazoles
Pyrimidines
Sulfonamides
pazopanib